BetterLife Pharma Inc BETRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BETRF is a good fit for your portfolio.
News
-
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
-
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
Trading Information
- Previous Close Price
- $0.07
- Day Range
- $0.07–0.07
- 52-Week Range
- $0.03–0.09
- Bid/Ask
- $0.06 / $0.08
- Market Cap
- $8.64 Mil
- Volume/Avg
- 500 / 29,039
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
Valuation
|
Metric
|
BETRF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BETRF
|
|---|---|
Quick Ratio | 0.02 |
Current Ratio | 0.08 |
Interest Coverage | −125.24 |
Quick Ratio
BETRF
Profitability
|
Metric
|
BETRF
|
|---|---|
Return on Assets (Normalized) | −438.73% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BETRF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vtyvlfqhmv | Gdn | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qcbhnykvt | Qvqphd | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mvzdmcbs | Gwktwq | $98.1 Bil | |
MRNA
| Moderna Inc | Hxxsmmkd | Vlfjf | $39.1 Bil | |
ARGX
| argenx SE ADR | Ybjpfznd | Cyx | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Vltdjyr | Mfq | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pvckjdyl | Zsnvgn | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vvtjvmhz | Rnzwvq | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zclkhhwbj | Hldxs | $12.5 Bil | |
INCY
| Incyte Corp | Rnsmztnz | Ctvttn | $11.9 Bil |